Mounjaro vs Retatrutide Side Effects: What Women Need to Know Before Choosing

Why Comparing These Two Drugs Is Complicated Right Now

No published trial has put Mounjaro and retatrutide in the same randomized comparison. Any side-effect comparison today draws on separate trials run in different populations, with different inclusion criteria and different follow-up durations. That caveat matters enormously for women, because the metabolic backdrop of your life stage (reproductive years, perimenopause, postmenopause) shapes both the side effects you experience and the weight loss you achieve.

What we do have: rich phase 3 data for tirzepatide across thousands of participants, and a high-quality phase 2 randomized controlled trial for retatrutide published in the New England Journal of Medicine in 2023. Reading them side by side, with attention to how women's physiology changes the picture, is exactly what this article does.

What Each Drug Is

Tirzepatide (Mounjaro, Zepbound) acts on two receptors: GLP-1 and GIP. GIP co-stimulation appears to reduce the nausea that pure GLP-1 agonists cause, though GI side effects are still the most common reason for dose adjustment.

Retatrutide adds a third target: the glucagon receptor. Glucagon stimulates energy expenditure and fat breakdown, which likely explains the larger weight-loss signal seen in phase 2. It also adds a different hormonal stress on metabolism, one whose long-term effect profile in women with baseline hormonal complexity (PCOS, perimenopausal estrogen flux, thyroid co-morbidity) has not yet been formally studied.

GI Side Effects: Where the Profiles Overlap Most

Both drugs cause gastrointestinal side effects as their primary tolerability issue. This is the class effect of GLP-1 receptor agonism: slower gastric emptying, reduced appetite signaling, and altered gut motility.

Tirzepatide GI Data From SURPASS-2

In SURPASS-2, the key NEJM 2021 trial comparing tirzepatide to semaglutide 1 mg in type 2 diabetes, nausea occurred in 17-22% of participants at 10 mg and 15 mg doses, vomiting in 9-13%, and diarrhea in 13-17%. Most events were mild to moderate and peaked during the titration phase in the first 12-20 weeks. Discontinuation due to GI adverse events was approximately 5% at the highest dose.

Women in GLP-1 trials historically report higher rates of nausea than men, a pattern observed with semaglutide in the STEP trials and now increasingly noted with tirzepatide in post-hoc analyses. Gastric emptying is already slower in women at baseline due to the effects of progesterone on gut motility, so the additive slowing from a GLP-1 agonist can be more pronounced.

Retatrutide GI Data From the Phase 2 Trial

In the Jastreboff et al. Phase 2 trial, nausea occurred in 45-65% of participants receiving retatrutide across dose groups (4 mg, 8 mg, 12 mg), compared with 16% in the placebo group. Vomiting rates ranged from 12-27% across dose groups. The 12 mg group, which produced the mean 24.2% body-weight reduction at 48 weeks, had the highest GI burden. Discontinuation due to adverse events was approximately 11-16% depending on dose, notably higher than what was seen in tirzepatide phase 3 trials.

These numbers are not directly comparable to SURPASS-2. The populations differ, the primary endpoints differ, and the phase 2 trial was not powered to characterize side effects with the same precision as a phase 3 program. Still, the signal is clear: retatrutide's GI burden in its current tested formulation appears higher, particularly at doses required for maximal weight loss.

Comparing the GI Profiles Side by Side

| Side Effect | Tirzepatide (SURPASS-2, 15 mg) | Retatrutide (Phase 2, 12 mg) | |---|---|---| | Nausea | ~22% | ~65% | | Vomiting | ~13% | ~27% | | Diarrhea | ~17% | ~23% | | Constipation | ~11% | ~13% | | GI-related discontinuation | ~5% | ~11-16% |

This framework will need updating once retatrutide phase 3 data are published. Phase 2 trials often show higher adverse-event rates because titration schedules are being tested and optimized; the final approved dose and schedule for retatrutide may carry a different tolerability profile.

Non-GI Side Effects: Where the Profiles Start to Diverge

Cardiovascular and Heart Rate

Tirzepatide modestly increases resting heart rate, by approximately 1-2 beats per minute on average at approved doses. This is a class effect shared with semaglutide. For most women this is clinically irrelevant, but for those with underlying arrhythmias, tachycardia, or known POTS (which disproportionately affects women of reproductive age), it warrants a conversation with your cardiologist.

Retatrutide's glucagon receptor activity adds a separate consideration. Glucagon is positively chronotropic, meaning it may push heart rate higher. In the phase 2 trial, heart rate increases with retatrutide were larger than those seen with GLP-1 monotherapy agents. The clinical significance in women without cardiovascular disease is uncertain at this stage, but it is a point of differentiation worth tracking as phase 3 data emerge.

Gallbladder Disease

Rapid weight loss with any agent increases cholelithiasis risk, because fat mobilization alters bile composition. Tirzepatide-related gallbladder events (gallstones, cholecystitis) occurred in approximately 1.6-2.4% of participants across SURPASS trials, consistent with or slightly lower than semaglutide rates.

Women are already at two to three times higher baseline risk for gallstones than men, a gap that widens during pregnancy and with oral estrogen use. If you are using combined hormonal contraception or systemic estrogen HRT alongside either drug, your gallbladder risk is additive. There are no head-to-head gallbladder data for retatrutide yet, but the phase 2 report noted gallbladder-related adverse events, and the greater magnitude of weight loss from retatrutide may translate into higher gallbladder risk.

Thyroid C-Cell Signal

Both drugs carry an FDA black box warning about thyroid C-cell tumors, based on rodent studies. This warning applies to the entire incretin receptor agonist class. The FDA prescribing information for tirzepatide states that human relevance of the rodent findings is unknown. Routine thyroid monitoring is not required, but both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). Retatrutide carries the same class-level concern.

Injection-Site Reactions

Tirzepatide injection-site reactions (erythema, pruritis, nodule) occur in approximately 3-7% of users based on pooled SURPASS data. Retatrutide showed similar rates in phase 2. Neither drug is associated with lipodystrophy at injection sites at current doses.

Women's Physiology: How Your Hormonal Status Changes the Side-Effect Picture

This section is why reading a general side-effect comparison is not enough. Women's hormonal environment actively modulates GI motility, drug metabolism, and appetite signaling.

Reproductive Years and the Menstrual Cycle

Progesterone in the luteal phase slows gastric emptying. If you take either drug, GI side effects may be noticeably worse in the 10-14 days before your period. This is not a sign of drug failure or allergy; it is progesterone physiology stacking on top of GLP-1-mediated slowing. Eating smaller meals and avoiding high-fat foods in the luteal phase reduces this overlap.

Women with PCOS often have baseline insulin resistance that makes them highly responsive to GLP-1-class agents, both in weight loss and in GI sensitivity. ACOG Practice Bulletin on PCOS acknowledges the metabolic complexity of PCOS. GLP-1 agents have been studied as off-label options for metabolic PCOS management, and their enhanced efficacy in this group may come paired with enhanced GI side effects. Starting at the lowest dose and titrating slowly matters more for women with PCOS, not less.

Perimenopause and Menopause

Estrogen has a protective effect on gut motility and appetite regulation. As estrogen declines in perimenopause (typically your early-to-mid 40s), visceral fat accumulates and insulin sensitivity worsens, which is why GLP-1 agents are increasingly used in this life stage. The flip side is that low estrogen may reduce the nausea-buffering effect that younger women's hormonal milieu provides, making perimenopausal and postmenopausal women potentially more sensitive to GI side effects at the same dose.

There are no published subgroup analyses of tirzepatide or retatrutide stratified by menopausal status. Women have historically been under-represented in metabolic drug trials, and menopausal status subgroups are even more rarely reported. This is a genuine evidence gap. What we extrapolate from GLP-1 class data and from estrogen physiology is reasonable but not confirmed by direct trial evidence.

Postpartum

If you are in the postpartum period and not breastfeeding, GLP-1 agents may be considered for postpartum weight retention after appropriate recovery, though specific guidance on timing is sparse. If you are breastfeeding, both drugs are contraindicated (see Pregnancy and Lactation section below).

Pregnancy, Lactation, and Contraception: Required Reading Before Starting Either Drug

Both tirzepatide and retatrutide are contraindicated in pregnancy. This is not a caution. It is a contraindication.

Tirzepatide in Pregnancy

Animal studies with tirzepatide showed embryo-fetal toxicity, reduced fetal weight, and skeletal abnormalities at exposures overlapping human therapeutic doses. The FDA prescribing label for tirzepatide advises discontinuing the drug at least 2 months before a planned pregnancy attempt, because tirzepatide has a half-life of approximately 5 days and takes 4-5 half-lives to clear, but a conservative margin is recommended given the embryotoxicity signal.

Human pregnancy data for tirzepatide are currently limited to case reports and registry data; no controlled human pregnancy study exists or is ethically feasible. The FDA Pregnancy and Lactation Labeling Rule requires manufacturers to collect and report postmarketing pregnancy outcomes; a registry is in place.

If you become pregnant while taking tirzepatide, stop the drug and contact your obstetric provider immediately.

Retatrutide in Pregnancy

Retatrutide has not completed phase 3 trials. No human pregnancy data exist. Given its mechanism overlaps substantially with tirzepatide and it adds glucagon receptor agonism, the same embryotoxicity concern applies. Treating retatrutide as contraindicated in pregnancy is the only responsible approach, and that is what its clinical trial protocols require.

Lactation

Tirzepatide transfer into human breast milk has not been formally studied. Given the molecular weight and lipophilicity of the drug, some transfer is biologically plausible. The prescribing label recommends against use during breastfeeding because of the potential for serious adverse reactions in the nursing infant, particularly related to GI development. The same applies to retatrutide.

Contraception Requirement

Both GLP-1-class agents slow gastric emptying, which may reduce the peak plasma concentration of oral hormonal contraceptives. Studies with semaglutide showed a reduction in ethinyl estradiol Cmax by approximately 20% with oral contraceptive co-administration. Tirzepatide carries a similar label advisory. If you rely on oral contraceptives for both contraception and cycle management (as many women with PCOS or endometriosis do), consider switching to a non-oral method (IUD, patch, ring, injectable) or using a barrier method alongside oral pills for at least the first 4 weeks after each dose increase.

Given the teratogenic potential of both agents, highly effective contraception is not optional for women of reproductive age taking either drug.

Who This Is Right For (and Not Right For), by Life Stage

Reproductive Years (18-39)

Mounjaro (tirzepatide) has the more complete safety and tolerability dataset. For women in their 20s and 30s who want a GLP-1-class agent for obesity or PCOS-related metabolic disease, tirzepatide is the evidence-backed choice today. Retatrutide may offer greater efficacy once approved, but its side-effect profile needs phase 3 confirmation and its interaction with the menstrual cycle and oral contraception needs dedicated study.

Not right for: women actively trying to conceive, pregnant women, breastfeeding women, or anyone with a history of medullary thyroid carcinoma or MEN2.

Perimenopause (40-52, roughly)

Both drugs may be particularly effective in perimenopause, because the estrogen-withdrawal-related insulin resistance at this life stage creates significant metabolic vulnerability. The greater weight-loss efficacy signal of retatrutide is theoretically appealing here. But the higher GI burden seen in phase 2 may be harder to tolerate if you are already dealing with hot flashes, sleep disruption, and the GI effects of changing estrogen levels. Tirzepatide is the practical starting point until retatrutide completes trials.

Postmenopause (52+)

Visceral fat accumulation and cardiovascular risk are highest in postmenopause. GLP-1-class agents have real cardiovascular data (SELECT trial with semaglutide; tirzepatide cardiovascular outcomes trial ongoing). For postmenopausal women, the side-effect burden may be more tolerable because the cycle-driven GI fluctuations are gone. Gallbladder risk remains a key monitoring point, especially if systemic HRT is used concurrently.

Efficacy Snapshot: Is the Extra Side-Effect Burden Worth It?

"The question is not just how much weight a drug removes, but whether a woman can stay on it long enough for that removal to matter," said Dr. Elena Vasquez, WomanRx board reviewer and obesity medicine specialist. "A 24% weight-loss potential means nothing if GI side effects force discontinuation at week 8."

This framing matters for comparing these two drugs. Tirzepatide delivered a mean 22.5% body-weight reduction at 72 weeks in SURMOUNT-1 at the 15 mg dose. Retatrutide delivered a mean 24.2% reduction at 48 weeks in the phase 2 trial at 12 mg. The retatrutide number is striking, but the follow-up was shorter, the population was smaller, and the discontinuation rate was higher. Longer follow-up with retatrutide may show weight regain after peak, as has been documented with semaglutide and tirzepatide after week 52-72.

For most women right now, tirzepatide offers a known side-effect profile, a manageable GI burden with slow titration, and a mature prescribing infrastructure. Retatrutide offers a larger weight-loss signal at the cost of a higher GI burden and a still-evolving safety map.

Can You Switch Between These Drugs?

No established clinical protocol exists for switching from tirzepatide to retatrutide or vice versa. When retatrutide becomes available, the transition approach will likely parallel switching between GLP-1 agents today: a washout period is typically not required between GLP-1-class agents, but the dose for the new drug should restart at the lowest titration step to avoid additive GI toxicity.

Before switching, the key questions are why you are switching, whether the reason is tolerability (GI side effects, injection-site issues, cost) or efficacy (inadequate weight loss), and whether you have current contraindications. If you are considering switching because of GI intolerance to tirzepatide, retatrutide's higher GI burden makes it an unlikely solution. If your reason is insufficient weight loss on maximum tirzepatide, retatrutide may eventually be a reasonable next step once it has phase 3 data and approval.

Monitoring and Practical Steps for Women on Either Drug

1. Track nausea by menstrual cycle phase. Luteal-phase nausea spikes are real and predictable.
2. Use a non-oral contraceptive method or add a barrier method, especially during dose escalation.
3. Get a baseline hepatic function panel. Both drugs are metabolized hepatically and have not been formally studied in severe hepatic impairment.
4. Monitor thyroid function if you have a personal or family history of thyroid disease. Postpartum thyroiditis affects approximately 5-10% of women after delivery and may be active during the period when postpartum women consider GLP-1 use.
5. Discuss gallbladder history. Women with prior gallstones or who are on oral estrogen have elevated baseline risk.
6. If you have PCOS, tell your prescriber. Insulin sensitization from these agents may reduce androgenic symptoms and affect cycle regularity, changes your gynecologist needs to track.
7. Stop either drug at least 2 months before any planned pregnancy attempt. Do not restart without obstetric clearance.